Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients
Margaret N. Kennedy, Astrid C. M. Andreescu, Marc S. Greenblatt et al. · British Journal of Haematology · 2005
Cancer patients have an increased risk of venous thrombosis (VT). The association of factor V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not established. We genotyped 101 cancer patients with VT and 101 cancer patients without VT for these polymorphisms. Five cases and three controls were heterozygous for FVL, yielding an odds ratio of 1.7 (95% confidence interval (CI) 0.3-10.7). Five cases and no controls were heterozygous for prothrombin 20210A, for an odds ratio of 6.7 (95% CI 0.9-infinity). Prothrombin 20210A may be associated with VT risk among cancer patients.
Cited by 44 works. doi:10.1111/j.1365-2141.2004.05327.x
Authors
- Margaret N. Kennedy
- Astrid C. M. Andreescu
- Marc S. Greenblatt
- Hongyu Jiang
- Christian A. Thomas
- Laurie Chassereau
- Cheung Wong
- Peter Durda
- Mary Cushman
References
- A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
- High-Throughput Genotyping with Single Nucleotide Polymorphisms
- Clinical significance of the FV:Q506 mutation in unselected oncology patients
- Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism
- Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma
- The factor V Leiden mutation in children with cancer and thrombosis
- Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter
- Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis
- Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations